摘要
胰腺癌是预后最差的肿瘤之一,其早期临床症状不明显,大部分病人确诊时已无手术机会,需要通过全身化疗来改善预后。因此,化疗仍是胰腺癌最重要的治疗选择之一。然而,化疗对晚期胰腺癌的生存期改善十分有限,化疗药物耐药是关键的原因之一。近年来大量研究开始聚焦于化疗耐药机制的探索,其中研究最为广泛的是吉西他滨耐药,其耐药机制复杂且不明确,肿瘤微环境的干涉、吉西他滨药物本身的代谢异常以及非编码RNA的调节均可能导致耐药的发生。针对上述可能存在的机制,可开发出潜在的抗耐药策略,提高化疗有效率,并改善胰腺癌的总体预后。
Pancreatic cancer remains a deadly malignancy with the worst prognosis. Due to disease presentation at an advanced stage, most patients are not qualified for surgical resection. Therefore, systemic chemotherapy is one of the most important treatments for pancreatic cancer. However,advanced pancreatic cancer has a very limited response to chemotherapy because of the chemoresistance. In recent years,a large number of studies have focused on the exploration of chemotherapy resistance mechanisms, especially gemcitabine resistance. The mechanism of gemcitabine resistance remains unclear. The influence of the tumor microenvironment, the abnormal intracellular metabolism of gemcitabine, and noncoding RNA regulation may lead to the drug resistance. In response to the possible mechanisms mentioned above,potential chemosensitization strategies can be developed to improve the effectiveness of chemotherapy and the overall survival of pancreatic cancer.
作者
央茂
冯佳毅
刘颖斌
YANG Mao;FENG Jia-yi;LIU Ying-bin(Department of Biliary and Pancreatic Surgery,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China)
出处
《中国实用外科杂志》
CAS
CSCD
北大核心
2022年第2期225-229,共5页
Chinese Journal of Practical Surgery
基金
国家自然科学基金(No.32130036)。
关键词
胰腺癌
化疗耐药
吉西他滨
肿瘤微环境
非编码RNA
pancreatic cancer
chemoresistance
gemcitabine
tumor microenvironment
non-coding RNA
